163 related articles for article (PubMed ID: 35390147)
1. Blocking human protein C anticoagulant activity improves clotting defects of hemophilia mice expressing human protein C.
Jiang M; Yang F; Jiang Y; Cheng L; Han J; Yi J; Zhang G; Ma Z; Cao L; Zuo B; Zhou L; Huang L; Niu S; Xia Z; Zhou X; Bai X; Esmon NL; Ruan C; Xia L; Han Y; Esmon CT; Wu D; Xu J
Blood Adv; 2022 Jun; 6(11):3304-3314. PubMed ID: 35390147
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of an anti-human APC antibody for prophylaxis of congenital factor deficiencies in preclinical models.
Jiang M; Yang F; Jiang Y; Cheng L; Han J; Yi J; Zuo B; Huang L; Ma Z; Li T; Cao LJ; Xia Z; Bai X; Jia C; Yang TTC; Esmon NL; Ruan C; Xia L; Esmon CT; Han Y; Wu D; Xu J
Blood; 2023 Sep; 142(12):1071-1081. PubMed ID: 37294924
[TBL] [Abstract][Full Text] [Related]
3. Selective inhibition of activated protein C anticoagulant activity protects against hemophilic arthropathy in mice.
Magisetty J; Kondreddy V; Keshava S; Das K; Esmon CT; Pendurthi UR; Rao LVM
Blood; 2022 May; 139(18):2830-2841. PubMed ID: 35143636
[TBL] [Abstract][Full Text] [Related]
4. Targeting protease nexin-1, a natural anticoagulant serpin, to control bleeding and improve hemostasis in hemophilia.
Aymonnier K; Kawecki C; Venisse L; Boulaftali Y; Christophe OD; Lenting PJ; Arocas V; de Raucourt E; Denis CV; Bouton MC
Blood; 2019 Nov; 134(19):1632-1644. PubMed ID: 31383642
[TBL] [Abstract][Full Text] [Related]
5. Improved hemostasis in hemophilia mice by means of an engineered factor Va mutant.
von Drygalski A; Cramer TJ; Bhat V; Griffin JH; Gale AJ; Mosnier LO
J Thromb Haemost; 2014; 12(3):363-72. PubMed ID: 24818532
[TBL] [Abstract][Full Text] [Related]
6. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
[TBL] [Abstract][Full Text] [Related]
7. An engineered factor Va prevents bleeding induced by anticoagulant wt activated protein C.
von Drygalski A; Bhat V; Gale AJ; Burnier L; Cramer TJ; Griffin JH; Mosnier LO
PLoS One; 2014; 9(8):e104304. PubMed ID: 25127130
[TBL] [Abstract][Full Text] [Related]
8. Absence of hematopoietic tissue factor pathway inhibitor mitigates bleeding in mice with hemophilia.
Maroney SA; Cooley BC; Ferrel JP; Bonesho CE; Nielsen LV; Johansen PB; Hermit MB; Petersen LC; Mast AE
Proc Natl Acad Sci U S A; 2012 Mar; 109(10):3927-31. PubMed ID: 22355108
[TBL] [Abstract][Full Text] [Related]
9. Prolonged α-thrombin-related activation and delayed active protein C-associated degradation confer mild phenotype in a patient with severe hemophilia A with F8 p.H118R.
Miyashita R; Shinozawa K; Inaba H; Amano K; Kinai E
Int J Hematol; 2022 Oct; 116(4):489-499. PubMed ID: 35590009
[TBL] [Abstract][Full Text] [Related]
10. Targeting activated protein C to treat hemophilia.
Polderdijk SGI; Baglin TP; Huntington JA
Curr Opin Hematol; 2017 Sep; 24(5):446-452. PubMed ID: 28632502
[TBL] [Abstract][Full Text] [Related]
11. Single-domain antibodies targeting antithrombin reduce bleeding in hemophilic mice with or without inhibitors.
Barbon E; Ayme G; Mohamadi A; Ottavi JF; Kawecki C; Casari C; Verhenne S; Marmier S; van Wittenberghe L; Charles S; Collaud F; Denis CV; Christophe OD; Mingozzi F; Lenting PJ
EMBO Mol Med; 2020 Apr; 12(4):e11298. PubMed ID: 32159286
[TBL] [Abstract][Full Text] [Related]
12. Emicizumab-mediated haemostatic function in patients with haemophilia A is down-regulated by activated protein C through inactivation of activated factor V.
Yada K; Nogami K; Shinozawa K; Kitazawa T; Hattori K; Amano K; Fukutake K; Shima M
Br J Haematol; 2018 Oct; 183(2):257-266. PubMed ID: 30125997
[TBL] [Abstract][Full Text] [Related]
13. General haemostatic agents--fact or fiction?
Hedner U
Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():33-6. PubMed ID: 12214145
[TBL] [Abstract][Full Text] [Related]
14. Serpins, New Therapeutic Targets for Hemophilia.
Aymonnier K; Kawecki C; Arocas V; Boulaftali Y; Bouton MC
Thromb Haemost; 2021 Mar; 121(3):261-269. PubMed ID: 32987444
[TBL] [Abstract][Full Text] [Related]
15. WAG-F8(m1Ycb) rats harboring a factor VIII gene mutation provide a new animal model for hemophilia A.
Booth CJ; Brooks MB; Rockwell S; Murphy JW; Rinder HM; Zelterman D; Paidas MJ; Compton SR; Marks PW
J Thromb Haemost; 2010 Nov; 8(11):2472-7. PubMed ID: 20626616
[TBL] [Abstract][Full Text] [Related]
16. [Haemophilia].
Loomans JI; Lock J; Peters M; Leebeek FW; Cnossen MH; Fijnvandraat K
Ned Tijdschr Geneeskd; 2014; 158():A7357. PubMed ID: 25351381
[TBL] [Abstract][Full Text] [Related]
17. Enhancing therapeutic efficacy of in vivo platelet-targeted gene therapy in hemophilia A mice.
Wang X; Fu RY; Li C; Chen CY; Firrman J; Konkle BA; Zhang J; Li L; Xiao W; Poncz M; Miao CH
Blood Adv; 2020 Nov; 4(22):5722-5734. PubMed ID: 33216891
[TBL] [Abstract][Full Text] [Related]
18. Combined coagulation factor VIII and factor IX deficiency (CDF8F9) in a patient from Lithuania.
Ivaškevičius V; Pezeshkpoor B; Biswas A; Goldmann G; Horneff S; Gimbutyte M; Malciute L; Jurgutis R; Oldenburg J
Hamostaseologie; 2016 Nov; 36(Suppl. 2):S29-S33. PubMed ID: 27824213
[TBL] [Abstract][Full Text] [Related]
19. A hemophilia A mouse model for the in vivo assessment of emicizumab function.
Ferrière S; Peyron I; Christophe OD; Kawecki C; Casari C; Muczynski V; Nathwani A; Kauskot A; Lenting PJ; Denis CV
Blood; 2020 Aug; 136(6):740-748. PubMed ID: 32369559
[TBL] [Abstract][Full Text] [Related]
20. The old and new: PCCs, VIIa, and long-lasting clotting factors for hemophilia and other bleeding disorders.
Ragni MV
Hematology Am Soc Hematol Educ Program; 2013; 2013():44-51. PubMed ID: 24319161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
